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ABSTRACT
Objective To examine how much oncologists tell patients
about the survival benefit of palliative chemotherapy
during consultations at which decisions about treatment
are made.
Design Qualitative study in which consultations were
observed and digitally recorded.
Setting Teaching hospital and district general hospital in
south west England.
Participants 37 patients with advanced non-small cell
lung cancer (n=12), pancreatic cancer (n=13), and
colorectal cancer (n=12); and nine oncologists, including
four consultants and five registrars.
Main outcome measures All recordings were transcribed
completely, anonymised, and electronically coded with
ATLAS.ti. Constant comparison was used to identify
themes and patterns. The framework method of data
management,inwhichdatawerecharted,wasusedtoaid
transparency of interpretation.
Results During the consultations, information given to
patients about survival benefit included numerical data
(“aboutfourweeks”),anideaoftimescales(“afewmonths
extra”), vague references (“buy you some time”), or no
mention at all. In most consultations (26/37) discussion
of survival benefit was vague or non-existent.
Conclusions Most patients were not given clear
information about the survival gain of palliative
chemotherapy. To aid decision making and informed
consent, we recommend that oncologists sensitively
describe the benefits and limitations of this treatment,
including survival gain.
INTRODUCTION
Every yearin the UnitedKingdommany thousandsof
patients are told they have incurable cancer and are
offered palliative chemotherapy. Such treatment com-
monly requires frequent visits to hospital and con-
siderable interruption to everyday activities. Because
of the considerable toxicity and the modest survival
benefits, decisions about treatment can be extremely
difficult.
The NHS cancer plan has emphasised the importance
of good communication between patients and the staff
caringforthem.
1Manypatientswantmoreinformation
about their disease and treatment options,
23and this is
important if patients are to exercise informed consent.
The Department of Health guide Consent—what you
have the right to expect indicates that “patients must be
given enough information to make a decision” and
suggests the sort of information health professionals
should offer, including “the benefits they hope will
result” and “the chances of getting such benefits.”
4
There is an increasing body of literature concerned
with communication and decision making,
5-8 and it is
recognised that doctors benefit from training in
“breaking bad news.”
910 For patients with advanced
cancer, however, thereis wide variation in the amount
of information given, and decision making aids are
scarce.
11-14
Survival benefit
Survivalbenefitisoftentheprimaryoutcomemeasure
inclinicalresearchrelatingtopalliativechemotherapy.
This suggests a difference in perspective between
palliative care clinicians, for whom “palliative” refers
to improvement in quality of life, and those clinicians
whofocusonprolonginglife.
1516Emphasisingsurvival
gain, however, might not be in conflict with the wishes
of patients. Many patients with advanced cancer
prioritise survival over quality of life
14 and oncologists
might “collude” with them in attempting to do some-
thing active about the disease.
17 The offer of active
treatment with palliative effects can support patients
through a process of adjustment from the distress of
diagnosistowardsgoalsotherthanlongtermsurvival.
18
But if survival benefit is not discussed when treatment
decisions are being made, there can be a considerable
gap between patients’ hopes and what can usually be
achieved.
The search for effective treatments continues but, at
the advanced stages of cancer, survival gain from
palliative chemotherapy tends to be months rather
than years. Statistics relating to survival benefit can be
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howpatientscanmakeinformeddecisionsifexpertsdo
not agree among themselves.
19 Furthermore, there are
concerns that the “intrusiveness of unfavourable
numbers” can undermine healthcare relationships
and destroy hope.
20 The challenge for oncologists,
andmulti-disciplinarycancerteams,istocommunicate
sufficient information to enable patients to make
informed decisions based on realistic aspirations
21 but
to do so in a sensitive manner and at the patient’s
pace.
22
We focused on qualitative data from oncology
consultations during a study of patients’ experiences
of treatments (ASPECTS) and examined the extent to
which survival gain was discussed when patients were
offered palliative chemotherapy.
METHODS
Study design and setting
Data for this paper come from the larger ASPECTS
study, which was conducted in the south west of
England. The study used qualitative research methods
to describe patients’ experiences of palliative che-
motherapy and to explore how the decision making
process might be improved in the light of those
experiences. During the main study an experienced
qualitativeresearcherinterviewedpatientsbeforethey
saw the oncologist; recorded and observed the initial
oncology consultation at which palliative chemother-
apy was discussed; and interviewed patients again, at
least once, in the weeks that followed. Relevant
oncologists consented to the observation and record-
ingofconsultationsandwerealsointerviewedtowards
the end of the study. Fieldwork took place in patients’
homes, a large teaching hospital, and a district general
hospital.
Three common cancers were chosen: colorectal,
non-smallcell lung,and pancreatic. Trialsare ongoing
but current UK guidelines suggest that palliative
chemotherapy might extend median survival by up
totwomonthsfornon-smallcelllungcancer
23andfrom
threetofourmonthstofivetosixmonthsforpancreatic
cancer.
24 For colorectal cancer median survival can
increase from five to nine months to between 7.5 and
14monthswithmonotherapyandby afurtherthreeto
five months with combination therapy.
2526
Recruitment
For the main study, clinical members of the research
team identified patients according to cancer site at
relevant multi-disciplinary team meetings. Patients
were considered suitable for the study if they had
locallyadvancedor metastaticdisease,had beengiven
a diagnosis, and had been offered an appointment to
see an oncologist. Relevant patients were informed
about the study and asked if they would be willing to
participate. Those who expressed an interest were
given an information leaflet and contacted by the
qualitative researcher. At a subsequent meeting, the
researcher explained the study again and patients who
agreed to participate signed the consent form. At each
stage it was made clear to patients that their medical
carewouldbeunaffectedwhetherornottheytookpart.
Forty five patients with advanced cancer were
recruited to the main study, 15 with each type of
cancer. This represents half of those who were
identified as suitable for the study (45/90). The main
reasons for non-recruitment were administrative diffi-
culties in contacting the patient because of the brief
time period before their first appointment with the
oncologist(n=16);patientsrefusedwithnoclearreason
given (n=11); patients or spouses indicated the patient
was too unwell or anxious to be interviewed (n=9); or
patients were unsuitable for another reason—for
example, elderly patients with dementia (n=6).
When appropriate we provided an information
leaflet, letter of invitation, and consent form for
partners and carers. Thirty three partners or carers
were recruited, indicating the extent to which this
experience was shared by patients and those closest to
them.
Process
The consultations were digitally recorded, and a non-
participant observed the consultation to capture non-
verbal communication. Video recording was not
practicable in the context of busy oncology clinics,
where the room allocated for a specific patient was not
always known in advance. In addition, the presence of
Table 1 |ExampleofFrameworkchartingfordatamanagementinmainstudy
Patient ID Sex Age (years) Cancer site Clinician ID
Treatment
decision
Quotes from oncologist
Purpose of treatment Survival benefit discussion
301 M 65 Lung 101 Chemotherapy
offered and
accepted
It’s a relatively uncommon situation and
normally if you can’t do an operation then
there’sverylittlechanceofcuringalungcancer
I’m afraid (cont…)
If we can’t achieve that, a cure, then we’re
looking to control it, shrink it, get rid of the
cough,buytime.InthissituationIthinkit’sabit
more unclear (cont…)
302 F 57 Pancreas 102 Chemotherapy
offered and
accepted
Now none of the drugs that have been
developed are cures and they don’tw o r kf o r
everybody. About 30% of people who receive
them (cont …)
You’ve got to be fit for it. Now with
chemotherapy, the benefit is not seen at all in
the people who would do very badly anyway,
right (cont…)
303 F 69 Colorectal 103 Chemotherapy
offered and
accepted
Nowthesituationisthatchemotherapyhasits
prosanditscons.Theproblemisthatwhenthe
cancer is widespread like this, treatment is
what we call palliative (cont…)
The aim of chemotherapy therefore is to keep
you going, not just to give you extra quantity of
lifebut extra quality oflife.The evidenceisthat
peoplewhorespondtotreatment,theygetboth
(cont…)
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thepatientshadalreadymetandwouldmeetagainwas
thought to be more appropriate and was in fact
regarded by some patients and their carers as a
“friendly face” at this difficult time. The researcher
didnottakenotesduringconsultationsasthiswaslikely
to be distracting for participants and might have
prompted concerns about what was being noted and
why. The researcher sat quietly in the corner of the
room and completed a reflective diary as soon as
possibleafterthe consultation.All the recordingswere
fully transcribed and anonymised to protect confiden-
tiality, and field notes were inserted in the text of
transcripts to highlight contextual issues where appro-
priate.
Analysis
During analysis we used the method of constant
comparison derived from grounded theory.
2728 We
readandre-readthetranscriptstobecomefamiliarwith
the data and revisited them at pertinent points
throughout the analysis. Data were electronically
coded with ATLAS.ti.
29 Codes and themes were
derivedfromissuesraisedbyparticipants,experiences
that recurredin the data, and the researchaims.Toaid
analysis, we adapted and used the Framework method
of qualitative data management.
2830 This entailed
“charting” the coded data. To explore information
giving during the consultations, we developed a chart
(table 1). Practitioners of Framework often handle
large amounts of data and, to make them more
manageable, summarise the original data before
entering them onto charts. The team was concerned
tocapturethisstageofinterpretationandsoweentered
original data relevant to the purpose of treatment and
survivalbenefitontoalargeprimarychartthatwasread
across rows for each patient and down columns to
compare experiences. During this process, variations
in the discussion of survival gain emerged.
We removed data less pertinent to this central issue
toproducesmallerchartswithafocusonsurvivalgain.
During this phase we eventually categorised the
survival benefit information as “numerical,”“ idea of
timescales,”“vague,”and“notdiscussed.”Thesecharts
were sorted—for example, by patients’ sex and cancer
site—to compare data relating to these subgroups and
look for patterns. Further reading and analysis,
including revisiting the primary chart and transcripts,
identifiedtriggersandbarrierstodiscussionofsurvival
gain. This method of data management promoted
transparency, enabling the research team to collec-
tively scrutinise each stage.
Participants
We observed and digitally recorded 37 oncology
consultations (three patients were too ill to keep the
appointment with the oncologist; two consultations
were not recorded; one patient refused to see an
oncologist; and the possibility of cure, judged to be
beyondthedefinitionofsurvivalbenefitforthispaper,
wasmentionedduringtwoconsultations).Wehavenot
included data from interviews before and after the
consultation because our primary concern was with
information given to the patient by the oncologist at
this initial consultation. We wanted to assess whether
the information provided at this stage was “enough
information to make a decision” and whether it
included “the benefits they [the oncologists] hope will
result”and“thechancesofgettingsuchbenefits”asthe
Department of Health guidance on seeking informed
consent to treatment suggests that it should.
4 Table 2
describes the patients included. The nine oncologists
who saw these patients were mixed in terms of age,
experience,andsex;andincludedfourconsultantsand
five registrars. (Further details are not given to protect
confidentiality.)
RESULTS
Purpose of treatment
Towards the beginning of the consultation all the
patients were informed that their cancer could not be
cured. For example:
Oncologist 102: None of the drugs that have been
developed are cures, and they don’t work for every-
body.
Oncologist 104: Whateverwe use, it won’t get rid of
it.
Oncologist112:Weknowthatwe’renotgoingtobe
able to cure your cancer for you.
Having established that the aim was not cure, the
oncologistsexplainedthemainpurposeofchemother-
apy either in terms of shrinking, slowing down,
controlling, or stabilising the tumour; improving
symptoms such as pain and weight loss; and/or
improving quality of life—for example, enabling
patients to feel “as well as possible for as long as
possible.”
Patientswhowereofferedchemotherapyweregiven
the names of relevant drugs; information about the
treatmentregimen;anddetailsofcommonsideeffects,
suchasnausea,andmeasurestoalleviatethem.Patients
were also warned of the increased risk of life threaten-
ing infections and what to do in an emergency. Those
who accepted chemotherapy signed consent forms to
Table 2 |Detailsof37patientswhoseoncologyconsultation
wasstudied
No of patients
Men 13
Women 24
Age (years):
≤50 1
51-59 8
60-69 11
70-79 16
≥80 1
Cancer site:
Colorectal 12
Lung 12
Pancreas 13
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were told that this did not commit them to having the
treatment if they subsequently decided against it, and
that the nurses responsible for administering che-
motherapy would explain the treatment again and
answerfurtherquestions.Whilethiswasdescribedasa
staged consent process, none of the patients who
consented at the initial oncology consultation subse-
quently refused treatment.
Survival benefit
Although there was consistency in informing patients
that a cure was not being sought, the amount of
information given about survival benefit varied con-
siderably(table 3).Thisrangedfromgivingnumerical
data, such as “about four weeks”; through an idea of
timescales, such as “a few months extra”; to vague
references, including “buy you some time”; to not
being mentioned at all. During the recorded consulta-
tions, only six of the 37 patients were given numerical
data about the survival benefit of treatment. These
included three of the 23 patients who accepted
palliative chemotherapy. In most consultations (26/
37) the discussion of survival benefit was either vague
or non-existent.
In qualitative research with small numbers we are
not looking for statistical significance but we did
scrutinise the data to see if there were any obvious
patterns.Nonewasfoundinrelationtothesexorageof
the patient, hospital site, cancer site, treatment
decision, or the actual survival of the patient (22
patients died during the course of the fieldwork).
Individual oncologists did not adopt a consistent
approach with all patients in relation to the amount of
information given about survival benefit (table 4).
Registrarsseemedlesslikelytodiscusstheissue,butthe
numbers are too small to draw any firm conclusions.
Triggers and barriers
By looking at the qualitative data in more detail we
could discern some triggers and barriers to discussion
of survival benefit. These are examined below and
illustrated with extracts from the transcripts.
Triggers
A few patients, or their relatives, specifically asked for
details. For example:
Son: And what’s the best you would expect with
that?
Oncologist 104: It may improve it by two to three
months.
Patient 335: Mm.
Oncologist 104: [to wife who was distressed] Is that
what you thought?
Wife: No, I’m afraid I didn’t give it much thought,
not in actual months.
Son:I’msorryIhadtoaskthatmum,becauseit’san
important part of making the decision isn’t it?
Wife: Yes, of course. I know that, yes.
Son: If you’re going to go through lots of pain and
problems.
Patient335:Ohyes.Em,Iem,Iwouldhaveaskedit
anyway if my son hadn’t.
Chemotherapy was offered and accepted; the patient
died two months later.
Sometimes the oncologist volunteered the informa-
tiontogivearealisticexpectationofwhatthetreatment
could achieve:
Oncologist 101: Now if somebody has chemo
therapy we’re, we’re not unfortunately talking about
peoplelivingyearslonger,we’retalkingaboutmonths
on the whole. Some lucky people may live some years
longer, but that’s not the average expectation.
Chemotherapy was offered and accepted; patient 309
died five months later.
Table 3 |Treatmentdecisionsanddiscussionofsurvivalbenefitinoncologyconsultations
Information about
survival benefit Total
Treatment decision
Chemotherapyofferedand
accepted
Chemotherapyofferedand
refused
Chemotherapy not
offered Further appointment
Numerical data 6 3 2 1 0
Idea of timescales 5 5 0 0 0
Vague 18 14 1 2 1
Not discussed 8 1 2 3 2
Total 37 23 5 6 3
Table 4 |Informationonsurvivalbenefitgiveninoncologyconsultations
Oncologist Numerical data Idea of timescales Vague Not discussed Total
101 — 53 — 8
102 2 — 3 — 5
103 1 — 53 9
104 3 — 21 6
107, 108, 110, 112, 113 —— 54 9
Total 6 5 18 8 37
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for some patients who decided that they did not want
chemotherapy and enabled them to justify their
decision, especially to family members who wanted
them to “fight” the disease:
Patient315:Offtherecord,doyouthink there’sany
benefit for me to have treatment?
Oncologist 103: The problem is I only know that
after the event.
Patient 315: After the event, yes.
Oncologist 103: My problem is I see it both sides.
Patient 315: Yeah.
Oncologist103:I’vegotsomepatientswho’vedone
verywellwiththesetreatmentsandhavelivedformuch
longer than frankly I would have expected.
Patient 315: Hmm mm.
Oncologist 103: I have other patients who either
have a lot of side effects with the treatment and no
benefit,or clearlygo throughit all and shortlyafter it’s
playingup,andwhatwouldbereallyhelpfulisifIcould
tellyouwhichofthosetwofolkthereyouweregoingto
beandthewholeprobleminthissituationisthatIcan’t.
Patient315:Myworsenightmarewouldprobablybe
to have some treatment and end up back in hospital
with another ailment.
Later in the consultation:
Patient’s wife: You’re going to fight it. You said you
would.
Patient315:Yeahbutitdoesn’tmeantosayit’sonly
goingtobeninemonthsImeanitmightbe12,itmight
be 15, it might be.
Oncologist 103: Averages are dangerous statistics.
Patient 315: Yeah, you never know. I said to you
beforeI’dsoonerhaveashortamountoftimewithabit
ofbonustoit,abitofbenefit.IfIhadtogointohospital
for five weeks every day and, and not benefit from it
and even catch something worse and end up back in
hospitalfortherestofmelifebasically,thenI’dhaveto
top myself.
Chemotherapy was offered and refused; the patient
died three months later.
Discussion of survival benefit was also helpful for
clinicians who had judged that patients were too ill to
tolerate the treatment. In such cases, oncologists could
point to the statistics on low survival benefit to show
that they were not withholding valuable treatment:
Oncologist 102: And even if it does work, it can
prolong life, but only by about four weeks. So it’s not
the answer, we know that, but it can be a dangerous
thing, and shouldn’t just be thrown about.
Chemotherapy was not prescribed; patient died two
weeks later.
Barriers
Some of these apparent triggers could also be barriers
to the discussion of survival benefit. If patients made it
clearfromtheoutsetthattheydidnotwantchemother-
apy, then the treatment might not be discussed in any
detail:
Patient 327: Chemotherapy that is completely out. I
don’t want that at all.
Oncologist 104: OK, right.
Patient327:IfI’mofferedtheopportunityofradio...
Oncologist 104: Yeah.
Patient 327: Em, and that would ease the pain . . .
Oncologist 104: Yeah.
Patient 327: I’m quite happy to have that.
Patient refused chemotherapy and received radio-
therapy; died three months later.
If oncologists judged patients to be too unwell for
chemotherapy,theconversationmightbesteeredaway
from the survival benefit of chemotherapy towards
recommending other medication:
Oncologist103:Idon’tthinkyourgeneralcondition
now would tolerate chemotherapy quite honestly.
Patient334:Wellno,Ithoughtitmightbuymesome
time, but I mean . . .
Oncologist 103: And I think the problem is that
because you’ve become so weak with it and lost so
much weight. . .
Patient 334: And you don’t want to eat.
Oncologist 103: Absolutely, and that’s one of the
commonest symptoms that the get-up-and-go gets up
and goes, and one just doesn’t want to.
Patient 334: Yes, and my get-up-and-go’s gone.
Oncologist103:Haveyoutriedsteroidsoranything
like that?
Patient 334: No, I, no.
Oncologist 103: Right. Well I think that will be a
worthwhilethingtodo,isforyoutohavesomesteroids
and something to stop them upsetting your stomach.
Steroids were prescribed; the patient died six weeks
later.
Emphasising the other benefits of chemotherapy
could also divert the conversation away from survival
benefit. This patient asked about life expectancy and
survival benefit,sayinghe was quitehappy tobe given
figures:
Box1Givinginformationaboutsurvivalgaintoapatientwithoutdiscussingprognosis
Oncologist101:Intermsofbenefitwe’dneedtoknowalsohowmuchextrabenefitinterms
of survival that people will get. The average is not very great. It’saf e wm o n t h s .B u tt h e
problemisthatsomepeoplewillget,youknow,ayearortwo.Somepeoplegetnobenefitat
all. And that’s why we can only sort of see whether it’s a useful treatment by trying it out for
oneortwotreatmentstosee,youknow,ifyou’resomebodywhogetsagoodresponsetothe
chemotherapy.Ifwedothatandwefindthatyouarerespondingwell,thetumour’sshrinking
andeverything’sgettingbetterthenwewillgoonuptofouroramaximumofsixtreatments
intotal.Andwe’dalsoaskthequestion“Isthereanybenefitfromradiotherapyattheendof
thatperiodoftreatment?”Ifyouweren’tgettingbenefitfromthechemotherapyandyouwere
still shortofbreaththen we would besayingwellperhapsweshould, could considersome
radiotherapy and stop the chemotherapy. So we’ll be making those decisions as we go
along.
Patient 346: As we, yeah. . .
Oncologist 101: And talking it through with you as we go step by step. That’sal o to f
information all at once, I’m sorry about that.
Patient 346: It’s all right, that, that’s why I have my, my daughter here. Chemotherapy was
offered and accepted; the patient was alive three months after consultation.
RESEARCH
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casesitcanactuallyreallyhelpwiththeircancersbutin
a lot of patients it can help with the symptoms.
Wife: Yes.
Oncologist 112: And this is why we give it.
Patient 339: Right
The oncologist did not give figures for life expectancy
or survival benefit. Chemotherapy was offered and
accepted; the patient was alive six months after
consultation.
Patients and their partners sometimes blocked the
discussion:
Oncologist103:Doyouwantmetotellyouwhatthe
statistics are?
Husband: Not particularly, do you?
Patient 303: No.
Husband: No.
Oncologist 103: The problem with statistics is they
don’ttellyouwhich,whichside,anditcomesdownto,
Is it worth it, going through this treatment? Is there
something that’s worthwhile going through all this
treatment, that I want to live longer or. . .
Husband: I think we have to make that decision as
well. I don’t think we want to go into the statistics.
Patient 303: Yeah.
Chemotherapy was offered and accepted; the patient
was alive 18 months after consultation.
Extracts from a consultation with a patient who was
distressedat the way in which shehad previously been
given her diagnosis, however, show the possibility of
imparting information about survival benefit while
respecting a patient’s wish not to discuss the prognosis
(box1).Theoncologistacknowledgedthedifficultiesof
being precise about survival gain but did indicate that
the “average” was “not great.” The inclusion of
information about range, as well as median survival
gain, softened the message and the patient seemed
satisfied with the level of information she had been
given.
DISCUSSION
For patients with advanced cancer to make informed
decisions about palliative chemotherapy, oncologists
need to describe the benefits and limitations of this
treatment, including survival benefit. The oncology
consultations studied here were important for several
reasons. These were the first consultations with an
oncologistafterpatientshadbeentoldtheircancerwas
advanced and a cure was not being sought; at which
patients expected to receive information from the
oncologist about further treatment options; and when
most patients consented to receive palliative che-
motherapy.
Impact on decision making
Study of the triggers and barriers to a discussion of
survival benefit during the consultations showed clear
implications for informed consent. In some oncology
consultations the decision making process included
giving patients information about the limited survival
benefit of treatment (box 2). For example, a direct
questionwasaskedandansweredgivingatleastanidea
of timescales; the patient refused treatment but was
aware of potential benefits including survival benefit;
the patient was informed of the reason why active
treatment was not being offered; and the oncologist
volunteered information to encourage realistic expec-
tations of what could be achieved.
We identified barriers to the discussion of survival
benefit that might undermine informed consent. If the
oncologist focuses on the benefits of palliative che-
motherapyintermsofcontrolofsymptomsandquality
oflife,butomitsinformationaboutsurvivalbenefit,the
patient might assume much greater potential to
prolong life than is likely to be the case. Conversely,
whenpatientsdeclinetheofferofpalliativechemother-
apy without a discussion of the potential benefits,
including survival gain, they might be basing their
decision on incomplete or inaccurate information.
Perhaps most difficult of all is when a patient, or their
partnerorcarer,makesitclearthattheydonotwantto
receive any more bad news. Talking about life
expectancy can seem cruel at this point. But, as has
been shown, supplying basic information about the
survival benefit of treatment need not entail giving
“intrusive” data about prognosis (see box 1).
Do patients want to know?
During the ASPECTS study, although patients and
their partners sometimes indicated that they did not
want to discuss prognosis at this stage, there was no
clearevidencethattheydidnotwantinformationabout
survivalgain,andsoitcannotbearguedthatclinicians
were simply responding to patients’ preferences.
Rather it seems that there is a tendency among
oncologists to conflate the two concepts, at least in
terms of what they consider might be helpful to the
patient. At oral presentations of these data (Joint
Box2Triggersandbarrierstoinformedconsentinoncologyconsultations
Triggers: survival benefit discussed
Patient
 Asking direct question*
 Justifying refusal
Oncologist
 Responding (numerical data/idea of timescales)
 Justifying no active treatment
 Volunteering information (realistic expectations)
Barriers: survival benefit not discussed or information is vague
Patient
 Is patient assuming lengthy survival?
 Not wanting treatment
 Blocking*
Oncologist
 Focusing on other benefits (symptom relief)
 Is patient aware of potential benefits?
 Responsibility to (sensitively) inform
*Or by partner/carer, withpatient’s agreement.
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International Epidemiological Association (European
Federation), University of Cork, Ireland, September
2007, and Annual research conference of Avon,
Somerset, and Wiltshire Cancer Research Network,
May 2008), some clinicians have suggested survival
gain can be discussed only in relation to overall life
expectancy, arguing, for example, that an additional
week can be very important to someone who might
have only a few weeks to live but can seem less
important to someone who might be expected to live
several more years. While this might be the case,
patients are unable to make this assessment if they are
not given the relevant information. Furthermore, it
couldbearguedthatpatientsmightacceptchemother-
apyiftheycanlookforwardtomanymonthsoryearsof
lifeafterthetreatment,butprefertheirfinalweekstobe
freefromthepotentialsideeffects.Suchargumentscan
only be speculative if the subject of survival gain is not
broached during the decision making process. In
practice, giving information about survival gain
might prompt patients to ask about prognosis or, as
has been illustrated here in relation to patient 346,
patientsmightindicatethattheydonotwanttodiscuss
prognosis at this stage.
Most patients have an ongoing relationship with
their doctor and not all information is given at one
consultation. For patients with advanced cancer,
however, it would be inappropriate to suggest that
information about available treatments, which could
influence their decision making, can be given after the
treatment has started.
Giving comprehensible and appropriate informa-
tion about survival benefit is extremely difficult. In
addition, the reluctance to inform patients of the
limited survival gain of palliative chemotherapy
might be motivated by a desire to “protect” patients
frombadnews,aswasoncethecaseinrelationtogiving
patients a diagnosis of cancer. The reluctance to
address these difficulties and sensitivities, however,
mightbehamperingpatients’abilitytomakeinformed
decisions about their future treatment.
Strengths and limitations
There have been few sound qualitative studies explor-
ing patients’ experiences of palliative chemotherapy.
These data contribute to this important yet under-
researchedtopic.Aswithallqualitativestudies,wedid
not have a large number of participants. Yet the range
of patients and oncologists involved, and the inclusion
of three cancer sites and two hospitals, suggest that the
findings could be transferable to other settings. A
further strength is the examination of data from
consultations as they occurred, rather than retro-
spective interviews with patients or their oncologists.
The sample of patients comprised a higher propor-
tionofmenthanmightbeexpectedamongthebroader
population of patients with these cancers. The ratio of
24:13, however, is in line with the wider ASPECTS
sample and with those who were eligible but not
recruited to the study. This would suggest that the
recruitment process was not biased in relation to sex.
Furthermore, there was no evidence that sex affected
the discussion of survival benefit.
Our results confirm previous research suggesting
that there is wide variation in the amount of informa-
tion given to patients.
11-14 As with all research, it is not
possible to rule out Hawthorne effects.
3132 The
presence of a researcher who observed and recorded
the consultations might have changed the content of
discussions. It could be argued, however, that this
might have encouraged oncologists to be more
thorough and to provide patients with more, rather
than less, information.
Implications for practice
It is now widely accepted that patients should be told if
they have cancer
33 and current guidance for oncologists
in “breaking bad news” includes how to convey an
unwelcome diagnosis. Accordingly, during ASPECTS,
the oncologists reinforced the diagnosis of advanced
cancer andexplainedthat, inprescribing chemotherapy
at this stage, a cure was not being sought. But current
guidance also places emphasis on informed decision
making. Evidence from ASPECTS suggests that onco-
logistsattempttomeetthisobligationbygivingdetailsof
thepotentialsideeffectsofchemotherapywithmuchless
time given to discussing the possible benefits of
treatment. Nevertheless, most patients accepted chemo-
therapy. This seems to be in line with the argument that
patients will risk negative impacts on quality of life for
survivalgain.
14Itisthereforeimportantthatpatientswith
advancedcanceraremadeawareofthelimitationsofthat
survivalgainduringthedecisionmakingprocess.While
it seems unlikely that this will change the treatment
decision for many patients, it will contribute to narrow-
ingthegapbetweenwhatoncologistscancurrentlyoffer
and what some patients hope for.
Thepriorityofinformingpatientshastobebalanced
against the emotional and psychological welfare of
those who are distressed by a diagnosis of incurable
cancer. Rather than evading this difficult subject, we
recommend that oncologists receive support and
training in how to communicate relevant information
aboutsurvivalbenefittotheirpatients.Mediansurvival
gain is a difficult concept and can be open to
misinterpretation but simple reassuring messages that
couldbegivenmightinclude:“Wearegoingtodoour
best for you”; “Our aim is to relieve your symptoms
and improve your quality of life”; “We also need to
consider what you would gain from this treatment in
terms of extra time”; “The average gain may be a few
monthsbutveryfewpeopleare“average”andsosome
people get quite a bit more than that, and sadly some
people get no benefit at all.”
Patients’ understanding of survival gain is also
pertinent to the debate about access to drugs through
theNationalHealthService.Whiledataaboutsurvival
gain are included in National Institute for Health and
Clinical Excellence (NICE) guidance for healthcare
professionals, they are omitted from the “information
for the public.”
34-38 Though the intent might be to
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patients’ hopes and what can usually be achieved. It
might also heighten concerns that valuable lifesaving
treatments are being withheld for purely economic
reasons. Consideration should be given as to whether,
and how, NICE should communicate this important
information to the public.
Greater awareness of survival gain might enable
some patients to adjust their aspirations. Others will
undoubtedly pin their hopes on being the exceptional
patient who flouts the available evidence. It is not the
joboftheoncologisttodenysuchhope,andfewwould
want to do so. The oncologists in this study acknowl-
edged that current palliative chemotherapy regimens
arenottheanswertothetreatmentofadvancedcancer.
Along with their patients, they hope for something
better in the future. In the meantime, by sensitively
narrowing the gap between unrealistic expectations
and current evidence, oncologists can be closer to
fulfilling their responsibility of assisting patients to
make informed decisions.
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